BJE6-106

立即咨询

BJE6-106

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1564249-38-2

包装与价格：

包装	价格(元)
10mM (in 1mL DMSO)	询价
5mg	询价
10mg	询价
50mg	询价
100mg	询价

BJE6-106 (B106) 是一种有效的选择性 PKCδ 抑制剂，IC50 值为 0.05 μM，BJE6-106 (B106) 靶向 PKCδ 的选择性是 PKC 同工酶 PKCα 的 1000倍 (IC50=50 μM)。BJE6-106 (B106) 可以诱导 caspase 依耐性细胞凋亡 (apoptosis)。BJE6-106 (B106) 具有肿瘤特异性作用。

Cas No.	1564249-38-2
别名	B106
Canonical SMILES	O=CC1=C2C(C=CC(C)(C)O2)=CC(CCN3C4=C(C5=C3C=CC=C5)C=CC=C4)=C1
分子式	C₂₆H₂₃NO₂
分子量	381.47
溶解度	Soluble in DMSO
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	BJE6-106 (B106) is a potent, selective 3rd generation PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC50=50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis. BJE6-106 (B106) possesses tumor-specific effect. PKCδ\|0.05 μM (IC50)\|PKCα\|50 μM (IC50) BJE6-106 (B106) (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations[1].BJE6-106 (B106) (0.2 μM, 0.5 μM; 6-24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells[1].BJE6-106 (B106) (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing MKK4, JNK and H2AX activation at different times in SBcl2 cells[1]. Cell Viability Assay[1] Cell Line: Melanoma cell lines with NRAS mutations: SBcl2, FM6, SKMEL2, WM1366, WM1361A, and WM852 cells [1]. Takashima A,et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014 Apr 18;9(4):1003-14.